CD274 and neoplasm: Beyond the PD-1/PD-L1 and CTLA-4 pathways, an increasing number of preclinical and clinical immunooncology studies explore the merits of additional checkpoint targets to mount broad anti-tumor immunity and mitigate treatment resistance.